Molecular Targets 2021: The Latest Efforts to Overcome Resistance to KRAS Inhibitors
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a...
Molecular Targets and Cancer Therapeutics Conference Moves Targeting KRAS to the Fore
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes...
Life in the RAS Lane: Frank McCormick and the Pursuit of Pancreatic Cancer’s Driver
Frank McCormick, PhD, FAACR, reflected on a career chasing the notorious RAS oncogene that earned him the inaugural Stephenson...
Annual Meeting 2022: KRAS, A History
When a patient receives a cancer diagnosis, doctors may perform genetic testing to determine what drives the cancer, potentially...
AACR Virtual Annual Meeting I: Identifying and Targeting RAS Regulatory Mechanisms
Signaling pathways that regulate cellular proliferation are commonly mutated in cancer cells, leading to unrestrained cellular division and tumor growth. Therefore, insight into the...
Driving Progress Against RAS-driven Cancers
Outside the lab, Frank McCormick, PhD, FAACR, is a racecar driver, nurturing a passion he developed decades ago. (“We...
AACR Annual Meeting 2023: Beating KRAS
The plenary program of the AACR Annual Meeting 2023 kicked off Saturday, April 15, with a session titled “Beating...
Editors’ Picks, January 2026: Naked Mole Rat’s Cancer Resistance, the Impact of Tissue and Liquid Biopsy Concordance, and More
What does a naked mole rat, a nuclear exporter that “moonlights” as a chromatin regulator, and the combined power...
Editors’ Picks, May 2024: Machine Learning in Cancer Research, the Cost of Smoking, and More
The editors of AACR's journals highlight studies from May, including machine learning, savings from quitting smoking, and more.
RAS as an ‘Undruggable’ Drug Target
Guest post by William G. Nelson, MD, PhDEditor-in-Chief, Cancer Today Mutant HRAS, KRAS, or NRAS genes have been found in...
AACR Virtual Annual Meeting I: Insights Gained from AACR Project GENIE
The unrestrained cellular proliferation that characterizes cancer largely arises due to genetic mutations, which can impede the regulatory mechanisms that control when and how often a cell divides. Genetic mutations may also...
Editors’ Picks, February 2026: FDA’s Accelerated Approval Pathway, Overcoming Resistance to KRAS Inhibition, and More
In February, the editors of AACR's journals highlighted studies on the FDA’s accelerated approval pathway, how metabolism impacts prostate...
Editors’ Picks: August Highlights from AACR Journals
For the month of August, the editors of the nine AACR journals have chosen to highlight results from two clinical...
Pancreatic Cancer: The Search for an Achilles Heel
Understanding pancreatic cancer’s strengths may provide clues to its weaknesses.
New Molecular Targets, Technologies, and Cancer Treatments Take Center Stage at the AACR-NCI-EORTC Conference
Promising early-phase clinical trial data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Old, New, Borrowed, and Blue: Clinical Trial Results Highlight Therapeutic Approaches for Non-small Cell Lung Cancer
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer....
Editors’ Picks: November Highlights from the AACR Journals
With Thanksgiving behind us here in the United States, the holiday season is in full swing. So, grab some...
Daily Recaps From the AACR Annual Meeting 2026: Sunday, April 19
A recap from the third day of the AACR Annual Meeting 2026, including the Opening Plenary, Clinical Trial Plenaries,...
AACR D3 Offered a Peek Into the Cancer Drug Pipeline, Innovative AI Tools, and More
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
Upcoming AACR Meeting Focuses on Recent Advances in Pancreatic Cancer Research
Pancreatic cancer is projected to become the second leading cause of cancer mortality in the United States by 2030....
January Editors’ Picks from AACR Journals
The new year has already ushered in some changes, but one thing stays the same. Each month, we’ll continue to feature the “must read” articles handpicked by the editors...
Editors’ Picks, June 2024: Metabolic Imaging, Practice-changing Adagrasib Trial, and More
The June edition of Editors’ Picks includes a clinical trial that clinched a new FDA approval for adagrasib, a...
AACR Annual Meeting 2025 Plenaries: Cancer Evolution, Tumor Microenvironment, Drugging KRAS, and More
The AACR Annual Meeting 2025, held April 25-30, featured six Plenary Sessions that explored exciting areas of cancer research,...
AACR Journal Editors Share “Must Read” Articles for February
Back for the month of February is our regular staple, Editors’ Picks, which features the “must read” articles that...
Editors’ Picks: June Highlights from the AACR Journals
For June, the editors of the AACR’s 10 journals chose to spotlight a characterization of an investigational KRAS inhibitor,...
The Best of 2022: FDA Approvals and the Breakthroughs That Enabled Them
The end of the year presents a unique opportunity to look back on recent accomplishments, take inventory of successes...
June Editors’ Picks from AACR Journals
Back for the month of June are the editors’ picks from the eight scientific journals published by the American...
Editors Share Highlights from September Issues of AACR Journals
As we unpack our cardigans in anticipation of cooler weather here on the East Coast, we are taking a...
Editors’ Picks, January 2025: Evolutionary Insights Into Cancer, Impact of Nicotine Levels in E-cigarettes, and More
As winter marches on, let’s dive into the cool articles highlighted this month by the editors of the AACR...
Daily Recaps From the AACR Annual Meeting 2026: Friday, April 17
A recap of the first day of the AACR Annual Meeting 2026, including coverage of educational sessions and other...